Illumina’s New Partnership Expands Genomic Testing in Breast Cancer
The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing.
Read MorePosted by Andy Lundin | Jan 12, 2022 | Breast |
The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing.
Read MorePosted by Andy Lundin | Jan 7, 2022 | Breast, Diagnostic Technologies |
BioReference will use Gestalt Diagnostic’s Digital Pathology solution with Mindpeak’s AI cancer diagnostics algorithm for quantification of cancer cells.
Read MorePosted by Andy Lundin | Jan 6, 2022 | Gastrointestinal Infections, Rapid Assays |
Meridian Bioscience says its Curian Campy assay—an immunoassay for the detection of a Campylobacter-specific antigen—received FDA clearance.
Read MorePosted by Andy Lundin | Jan 6, 2022 | Prostate, Rapid Assays |
A portable and rapid prostate cancer screening kit could provide early warning to populations with higher incidence of prostate cancer.
Read MorePosted by Andy Lundin | Jan 4, 2022 | Covid 19, Immunoassay Reagents & test Kits |
The FINDER 1.5 testing platform has the speed of a rapid antigen test and accuracy of an RT-PCR lab test.
Read More